Showing 371-380 of 708 results for "".
Clinical Data Prompting Guideline Updates for Subcutaneous ICIs in Melanoma
https://practicaldermatology.com/programs/cme/clinical-data-prompting-guideline-updates-for-subcutaneous-icis-in-melanoma/36329/Explore guideline-based treatment strategies and clinical data to optimize guideline-concordant care for patients with melanoma in the neoadjuvant, adjuvant, and metastatic settings.Clinical Implications of Neoadjuvant Therapy Guideline Updates in Resectable Melanoma
https://practicaldermatology.com/programs/cme/clinical-implications-of-neoadjuvant-therapy-guideline-updates-in-resectable-melanoma/36323/Explore guideline-based treatment strategies and clinical data to optimize guideline-concordant care for patients with melanoma in the neoadjuvant, adjuvant, and metastatic settings.Verrucous Psoriasis
https://practicaldermatology.com/topics/psoriasis/verrucous-psoriasis/27148/Verrucous psoriasis (VP) is a rare subtype of psoriasis most commonly affecting middle-aged to older adults, with fewer than 35 reported cases within the current literature. It is characterized by symmetric wart-like, hyperkeratotic, papillomatous plaques. Treatment options are limited and variable,Repairing the Ellipse; Resident Salary Update
https://practicaldermatology.com/youngmd-connect/resident-resource-center/repairing-the-ellipse-resident-salary-update/20414/Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage III/IV Melanoma
https://practicaldermatology.com/programs/cme/efficacy-and-safety-outcomes-for-adjuvant-immunotherapy-driving-guideline-recommendations-for-stage-iiiiv-melanoma/36325/Explore guideline-based treatment strategies and clinical data to optimize guideline-concordant care for patients with melanoma in the neoadjuvant, adjuvant, and metastatic settings.Data Driving Preferred Guideline Recommendations in First-Line Therapy for Metastatic Melanoma
https://practicaldermatology.com/programs/cme/data-driving-preferred-guideline-recommendations-in-first-line-therapy-for-metastatic-melanoma/36327/Explore guideline-based treatment strategies and clinical data to optimize guideline-concordant care for patients with melanoma in the neoadjuvant, adjuvant, and metastatic settings.Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed Stage III Melanoma
https://practicaldermatology.com/programs/cme/implementing-guideline-concordant-care-for-a-patient-with-newly-diagnosed-stage-iii-melanoma/36326/Explore guideline-based treatment strategies and clinical data to optimize guideline-concordant care for patients with melanoma in the neoadjuvant, adjuvant, and metastatic settings.Insights From Global Key Opinion Leaders on Regional Regulatory and Guideline Nuances to Optimize Melanoma Management
https://practicaldermatology.com/programs/cme/insights-from-global-key-opinion-leaders-on-regional-regulatory-and-guideline-nuances-to-optimize-melanoma-management/36331/Explore guideline-based treatment strategies and clinical data to optimize guideline-concordant care for patients with melanoma in the neoadjuvant, adjuvant, and metastatic settings.Comorbidities in Vitiligo
https://practicaldermatology.com/issues/august-2025/comorbidities-in-vitiligo/36702/Vitiligo is a chronic, acquired pigmentary disorder characterized by the progressive loss of function or destruction of melanocytes in the skin, hair follicles, and mucous membranes. In this piece, Dr. Brad Glick and colleagues explore comorbidities in vitiligo.Recent Developments
https://practicaldermatology.com/columns/recent-developments/recent-developments-40/23808/